| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Colorectal Neoplasms | 36 | 2024 | 981 | 7.960 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 12 | 2022 | 42 | 5.200 |
Why?
|
| Genetic Testing | 14 | 2024 | 537 | 4.020 |
Why?
|
| Carcinoma, Pancreatic Ductal | 5 | 2024 | 112 | 2.690 |
Why?
|
| Colon | 8 | 2023 | 509 | 2.640 |
Why?
|
| Celiac Disease | 13 | 2019 | 213 | 2.640 |
Why?
|
| Early Detection of Cancer | 11 | 2024 | 415 | 2.280 |
Why?
|
| Calcitriol | 4 | 2021 | 173 | 2.250 |
Why?
|
| Pancreatic Neoplasms | 7 | 2024 | 667 | 2.220 |
Why?
|
| Genetic Predisposition to Disease | 20 | 2024 | 2335 | 1.660 |
Why?
|
| Colonoscopy | 12 | 2023 | 279 | 1.640 |
Why?
|
| Neoplastic Syndromes, Hereditary | 4 | 2020 | 18 | 1.560 |
Why?
|
| Epigenomics | 2 | 2023 | 103 | 1.530 |
Why?
|
| Genetic Counseling | 4 | 2022 | 101 | 1.430 |
Why?
|
| Vitamin D | 7 | 2017 | 268 | 1.370 |
Why?
|
| Organoids | 5 | 2023 | 62 | 1.360 |
Why?
|
| DNA Mismatch Repair | 6 | 2024 | 55 | 1.230 |
Why?
|
| Uridine Phosphorylase | 2 | 2018 | 4 | 1.220 |
Why?
|
| Humans | 97 | 2024 | 89073 | 1.190 |
Why?
|
| Glutens | 6 | 2019 | 83 | 1.170 |
Why?
|
| Heterozygote | 7 | 2024 | 373 | 1.110 |
Why?
|
| Germ-Line Mutation | 7 | 2024 | 344 | 1.090 |
Why?
|
| Polymorphism, Single Nucleotide | 10 | 2017 | 2399 | 1.030 |
Why?
|
| Gastroenterology | 5 | 2021 | 144 | 0.990 |
Why?
|
| Patient Compliance | 2 | 2018 | 230 | 0.990 |
Why?
|
| Colonic Polyps | 3 | 2022 | 132 | 0.960 |
Why?
|
| Middle Aged | 41 | 2024 | 25865 | 0.930 |
Why?
|
| Patient Advocacy | 1 | 2023 | 52 | 0.840 |
Why?
|
| Stomach Neoplasms | 4 | 2024 | 281 | 0.840 |
Why?
|
| Adenoma | 3 | 2022 | 246 | 0.820 |
Why?
|
| Male | 43 | 2024 | 42254 | 0.820 |
Why?
|
| Peutz-Jeghers Syndrome | 1 | 2022 | 8 | 0.810 |
Why?
|
| HLA-DQ Antigens | 3 | 2019 | 51 | 0.810 |
Why?
|
| Aspirin | 1 | 2023 | 159 | 0.790 |
Why?
|
| Glucocorticoids | 2 | 2014 | 357 | 0.780 |
Why?
|
| Risk Factors | 17 | 2024 | 5466 | 0.780 |
Why?
|
| Fellowships and Scholarships | 1 | 2023 | 121 | 0.770 |
Why?
|
| Female | 46 | 2024 | 46014 | 0.770 |
Why?
|
| Aged | 27 | 2024 | 19078 | 0.750 |
Why?
|
| Transcription, Genetic | 3 | 2017 | 1157 | 0.750 |
Why?
|
| Health Policy | 2 | 2021 | 184 | 0.740 |
Why?
|
| Inflammatory Bowel Diseases | 3 | 2017 | 575 | 0.730 |
Why?
|
| Intestine, Small | 3 | 2024 | 299 | 0.730 |
Why?
|
| Adenomatous Polyposis Coli | 4 | 2021 | 39 | 0.730 |
Why?
|
| Diet, Gluten-Free | 3 | 2019 | 57 | 0.710 |
Why?
|
| Food Handling | 1 | 2019 | 6 | 0.700 |
Why?
|
| Health Status Disparities | 3 | 2021 | 187 | 0.700 |
Why?
|
| Legislation, Medical | 1 | 2019 | 9 | 0.660 |
Why?
|
| BRCA2 Protein | 1 | 2020 | 161 | 0.660 |
Why?
|
| Biomarkers, Tumor | 7 | 2024 | 1543 | 0.650 |
Why?
|
| BRCA1 Protein | 1 | 2020 | 204 | 0.640 |
Why?
|
| Genetic Variation | 4 | 2020 | 1371 | 0.640 |
Why?
|
| Endoscopy, Gastrointestinal | 2 | 2019 | 157 | 0.630 |
Why?
|
| Uridine | 1 | 2018 | 56 | 0.630 |
Why?
|
| Intestinal Diseases | 1 | 2019 | 79 | 0.620 |
Why?
|
| Transcriptome | 2 | 2021 | 628 | 0.620 |
Why?
|
| Colonic Diseases | 1 | 2018 | 61 | 0.610 |
Why?
|
| Retrospective Studies | 14 | 2024 | 9003 | 0.600 |
Why?
|
| Receptors, Calcitriol | 3 | 2018 | 130 | 0.600 |
Why?
|
| Gene Expression Regulation | 3 | 2017 | 1975 | 0.600 |
Why?
|
| Cell Proliferation | 2 | 2014 | 1650 | 0.600 |
Why?
|
| United States | 16 | 2023 | 6957 | 0.600 |
Why?
|
| Postoperative Period | 1 | 2018 | 301 | 0.600 |
Why?
|
| Medicare | 1 | 2021 | 423 | 0.600 |
Why?
|
| Hematoma | 1 | 2018 | 108 | 0.590 |
Why?
|
| Blood Coagulation Disorders | 1 | 2018 | 66 | 0.580 |
Why?
|
| Biopsy | 8 | 2021 | 1182 | 0.580 |
Why?
|
| Jejunal Neoplasms | 1 | 2017 | 9 | 0.580 |
Why?
|
| Hamartoma Syndrome, Multiple | 1 | 2017 | 11 | 0.570 |
Why?
|
| Cadherins | 4 | 2024 | 163 | 0.570 |
Why?
|
| Patient Selection | 3 | 2019 | 682 | 0.560 |
Why?
|
| Epithelial Cells | 2 | 2018 | 688 | 0.560 |
Why?
|
| Practice Guidelines as Topic | 3 | 2021 | 1043 | 0.540 |
Why?
|
| DNA Damage | 1 | 2018 | 371 | 0.540 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2019 | 237 | 0.540 |
Why?
|
| Genomics | 2 | 2021 | 761 | 0.530 |
Why?
|
| Mass Screening | 2 | 2023 | 636 | 0.530 |
Why?
|
| Breast Neoplasms | 4 | 2024 | 3000 | 0.520 |
Why?
|
| Attitude | 1 | 2016 | 130 | 0.510 |
Why?
|
| Referral and Consultation | 1 | 2018 | 341 | 0.510 |
Why?
|
| Adult | 28 | 2024 | 26508 | 0.500 |
Why?
|
| Precision Medicine | 1 | 2019 | 410 | 0.500 |
Why?
|
| Antigens, CD | 3 | 2024 | 466 | 0.500 |
Why?
|
| Microsatellite Instability | 5 | 2024 | 49 | 0.480 |
Why?
|
| Quantitative Trait Loci | 2 | 2017 | 607 | 0.480 |
Why?
|
| Bone Morphogenetic Protein 4 | 1 | 2014 | 15 | 0.470 |
Why?
|
| Predictive Value of Tests | 7 | 2020 | 1715 | 0.460 |
Why?
|
| Family | 1 | 2015 | 325 | 0.440 |
Why?
|
| Genome-Wide Association Study | 6 | 2017 | 1670 | 0.440 |
Why?
|
| Chromosomes, Human, Pair 8 | 2 | 2012 | 85 | 0.430 |
Why?
|
| Adenocarcinoma | 4 | 2024 | 1194 | 0.420 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2013 | 207 | 0.420 |
Why?
|
| DNA, Neoplasm | 2 | 2010 | 268 | 0.420 |
Why?
|
| Brain Neoplasms | 1 | 2018 | 781 | 0.420 |
Why?
|
| Diet | 5 | 2021 | 442 | 0.410 |
Why?
|
| Physicians | 2 | 2019 | 689 | 0.410 |
Why?
|
| Polymorphism, Genetic | 2 | 2018 | 824 | 0.390 |
Why?
|
| Time Factors | 8 | 2021 | 5320 | 0.380 |
Why?
|
| Aged, 80 and over | 9 | 2024 | 6777 | 0.380 |
Why?
|
| Incidence | 5 | 2021 | 1592 | 0.350 |
Why?
|
| Young Adult | 9 | 2021 | 6289 | 0.350 |
Why?
|
| Chromatin | 2 | 2023 | 397 | 0.330 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2014 | 559 | 0.330 |
Why?
|
| Adaptive Immunity | 3 | 2015 | 167 | 0.330 |
Why?
|
| Mismatch Repair Endonuclease PMS2 | 3 | 2019 | 24 | 0.320 |
Why?
|
| Vitamin D3 24-Hydroxylase | 2 | 2021 | 6 | 0.310 |
Why?
|
| Case-Control Studies | 9 | 2024 | 1855 | 0.310 |
Why?
|
| Colitis, Ulcerative | 2 | 2014 | 736 | 0.310 |
Why?
|
| Mutation | 3 | 2017 | 4132 | 0.300 |
Why?
|
| Cholestasis, Intrahepatic | 1 | 2007 | 14 | 0.300 |
Why?
|
| Mastocytosis | 1 | 2007 | 13 | 0.300 |
Why?
|
| T-Lymphocytes | 1 | 2014 | 1223 | 0.300 |
Why?
|
| Quality of Life | 1 | 2016 | 1662 | 0.300 |
Why?
|
| Crohn Disease | 1 | 2014 | 758 | 0.300 |
Why?
|
| Vitamins | 2 | 2021 | 83 | 0.290 |
Why?
|
| DNA-Binding Proteins | 6 | 2022 | 1241 | 0.280 |
Why?
|
| Tissue Culture Techniques | 2 | 2018 | 81 | 0.270 |
Why?
|
| Risk Assessment | 6 | 2024 | 2291 | 0.260 |
Why?
|
| DNA Mutational Analysis | 3 | 2021 | 529 | 0.260 |
Why?
|
| Intestinal Mucosa | 4 | 2019 | 805 | 0.250 |
Why?
|
| Inflammation | 4 | 2020 | 971 | 0.250 |
Why?
|
| Colonic Neoplasms | 4 | 2020 | 573 | 0.250 |
Why?
|
| MutL Protein Homolog 1 | 4 | 2022 | 33 | 0.250 |
Why?
|
| DNA Methylation | 4 | 2020 | 657 | 0.250 |
Why?
|
| Interleukin-15 | 3 | 2015 | 73 | 0.240 |
Why?
|
| Adaptor Proteins, Signal Transducing | 3 | 2015 | 313 | 0.240 |
Why?
|
| T-Lymphocytes, Cytotoxic | 2 | 2015 | 319 | 0.230 |
Why?
|
| Biomarkers | 3 | 2019 | 1755 | 0.230 |
Why?
|
| Phenotype | 3 | 2020 | 2439 | 0.220 |
Why?
|
| Social Welfare | 1 | 2023 | 19 | 0.220 |
Why?
|
| Perception | 1 | 2024 | 178 | 0.210 |
Why?
|
| Prospective Studies | 4 | 2024 | 4273 | 0.210 |
Why?
|
| Rectal Neoplasms | 1 | 2023 | 127 | 0.210 |
Why?
|
| Age of Onset | 2 | 2021 | 312 | 0.210 |
Why?
|
| Age Factors | 3 | 2020 | 1867 | 0.210 |
Why?
|
| Counselors | 1 | 2022 | 4 | 0.200 |
Why?
|
| Intestinal Polyps | 1 | 2022 | 27 | 0.200 |
Why?
|
| Alleles | 2 | 2017 | 1135 | 0.200 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 2 | 2014 | 181 | 0.200 |
Why?
|
| Chicago | 3 | 2014 | 1423 | 0.200 |
Why?
|
| ErbB Receptors | 2 | 2018 | 500 | 0.200 |
Why?
|
| MicroRNAs | 2 | 2020 | 551 | 0.200 |
Why?
|
| Point-of-Care Systems | 1 | 2023 | 148 | 0.200 |
Why?
|
| Surveys and Questionnaires | 2 | 2023 | 2612 | 0.200 |
Why?
|
| Mucous Membrane | 1 | 2022 | 83 | 0.200 |
Why?
|
| Text Messaging | 1 | 2022 | 31 | 0.200 |
Why?
|
| MutS Homolog 2 Protein | 3 | 2019 | 30 | 0.200 |
Why?
|
| Gene Frequency | 3 | 2014 | 685 | 0.190 |
Why?
|
| Southeastern United States | 1 | 2021 | 8 | 0.190 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2022 | 128 | 0.190 |
Why?
|
| Occult Blood | 1 | 2021 | 17 | 0.190 |
Why?
|
| Endometrial Neoplasms | 1 | 2024 | 205 | 0.190 |
Why?
|
| Sex Factors | 2 | 2015 | 1063 | 0.190 |
Why?
|
| Delayed Diagnosis | 1 | 2021 | 32 | 0.190 |
Why?
|
| Deoxyribonuclease (Pyrimidine Dimer) | 1 | 2021 | 1 | 0.190 |
Why?
|
| Life Style | 2 | 2023 | 172 | 0.190 |
Why?
|
| Gene-Environment Interaction | 2 | 2012 | 111 | 0.190 |
Why?
|
| Evidence-Based Medicine | 2 | 2021 | 433 | 0.190 |
Why?
|
| Microbiota | 2 | 2017 | 398 | 0.180 |
Why?
|
| Meningeal Neoplasms | 1 | 2021 | 65 | 0.180 |
Why?
|
| Meningioma | 1 | 2021 | 63 | 0.180 |
Why?
|
| Geography | 1 | 2021 | 227 | 0.180 |
Why?
|
| Immunity, Innate | 2 | 2014 | 429 | 0.180 |
Why?
|
| Treatment Outcome | 6 | 2018 | 8203 | 0.180 |
Why?
|
| Transcriptional Activation | 1 | 2021 | 291 | 0.170 |
Why?
|
| Chemoprevention | 2 | 2018 | 92 | 0.170 |
Why?
|
| Stem Cells | 1 | 2022 | 372 | 0.170 |
Why?
|
| Health Behavior | 1 | 2021 | 184 | 0.170 |
Why?
|
| Antigens | 2 | 2019 | 229 | 0.170 |
Why?
|
| Diagnosis, Differential | 2 | 2018 | 1591 | 0.170 |
Why?
|
| Lobbying | 1 | 2019 | 3 | 0.170 |
Why?
|
| Intestinal Absorption | 1 | 2019 | 124 | 0.170 |
Why?
|
| Duodenum | 1 | 2019 | 103 | 0.170 |
Why?
|
| Federal Government | 1 | 2019 | 29 | 0.170 |
Why?
|
| Endoscopy | 1 | 2022 | 348 | 0.170 |
Why?
|
| Cross-Sectional Studies | 3 | 2019 | 1706 | 0.160 |
Why?
|
| Food | 1 | 2019 | 89 | 0.160 |
Why?
|
| Th1 Cells | 2 | 2017 | 166 | 0.160 |
Why?
|
| Health Surveys | 1 | 2019 | 240 | 0.160 |
Why?
|
| Carcinoembryonic Antigen | 1 | 2018 | 40 | 0.160 |
Why?
|
| Capsule Endoscopy | 1 | 2019 | 33 | 0.160 |
Why?
|
| Adenomatous Polyposis Coli Protein | 1 | 2018 | 41 | 0.160 |
Why?
|
| Checkpoint Kinase 2 | 1 | 2018 | 26 | 0.160 |
Why?
|
| Up-Regulation | 3 | 2020 | 727 | 0.160 |
Why?
|
| Adolescent | 6 | 2020 | 9237 | 0.160 |
Why?
|
| Cancer Care Facilities | 1 | 2018 | 29 | 0.160 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2018 | 73 | 0.160 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 1 | 2018 | 55 | 0.160 |
Why?
|
| Artificial Intelligence | 1 | 2022 | 322 | 0.160 |
Why?
|
| Whipple Disease | 1 | 2018 | 1 | 0.160 |
Why?
|
| Tropheryma | 1 | 2018 | 1 | 0.160 |
Why?
|
| Microsatellite Repeats | 1 | 2018 | 147 | 0.160 |
Why?
|
| Aberrant Crypt Foci | 1 | 2018 | 7 | 0.160 |
Why?
|
| Ileum | 1 | 2019 | 160 | 0.160 |
Why?
|
| Cytoprotection | 1 | 2018 | 47 | 0.160 |
Why?
|
| Laxatives | 1 | 2018 | 13 | 0.150 |
Why?
|
| Receptors, Antigen, T-Cell, gamma-delta | 1 | 2019 | 105 | 0.150 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2018 | 2657 | 0.150 |
Why?
|
| Adenomatous Polyps | 1 | 2017 | 13 | 0.150 |
Why?
|
| Colitis | 1 | 2020 | 244 | 0.150 |
Why?
|
| Prostatic Neoplasms | 1 | 2009 | 1768 | 0.150 |
Why?
|
| Anticarcinogenic Agents | 1 | 2018 | 73 | 0.150 |
Why?
|
| Interferon Type I | 2 | 2017 | 178 | 0.150 |
Why?
|
| Digestive System Neoplasms | 1 | 2017 | 21 | 0.150 |
Why?
|
| Reoviridae Infections | 1 | 2017 | 7 | 0.150 |
Why?
|
| Avena | 1 | 2017 | 17 | 0.150 |
Why?
|
| Transcription Factors | 2 | 2023 | 1652 | 0.140 |
Why?
|
| Research Support as Topic | 1 | 2017 | 85 | 0.140 |
Why?
|
| Promoter Regions, Genetic | 2 | 2018 | 956 | 0.140 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2018 | 217 | 0.140 |
Why?
|
| Colonography, Computed Tomographic | 1 | 2017 | 81 | 0.140 |
Why?
|
| Pharmaceutical Research | 1 | 2016 | 2 | 0.140 |
Why?
|
| Organ Culture Techniques | 1 | 2017 | 135 | 0.140 |
Why?
|
| Neoplasms, Second Primary | 1 | 2019 | 260 | 0.140 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2017 | 125 | 0.140 |
Why?
|
| Drug Monitoring | 1 | 2017 | 119 | 0.140 |
Why?
|
| Drug Evaluation | 1 | 2016 | 138 | 0.140 |
Why?
|
| Healthcare Disparities | 1 | 2021 | 410 | 0.140 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2017 | 136 | 0.130 |
Why?
|
| Gastrointestinal Diseases | 1 | 2017 | 151 | 0.130 |
Why?
|
| Drug Approval | 1 | 2016 | 66 | 0.130 |
Why?
|
| Polyethylene Glycols | 1 | 2018 | 358 | 0.130 |
Why?
|
| Leukotrienes | 1 | 2015 | 20 | 0.130 |
Why?
|
| NK Cell Lectin-Like Receptor Subfamily K | 1 | 2015 | 32 | 0.130 |
Why?
|
| Dietary Supplements | 1 | 2016 | 125 | 0.130 |
Why?
|
| Genotype | 4 | 2017 | 1848 | 0.130 |
Why?
|
| Gastrointestinal Agents | 1 | 2017 | 171 | 0.130 |
Why?
|
| Binding Sites | 1 | 2018 | 1117 | 0.130 |
Why?
|
| Overweight | 1 | 2016 | 119 | 0.130 |
Why?
|
| Mice | 6 | 2022 | 11742 | 0.130 |
Why?
|
| DNA Repair Enzymes | 1 | 2015 | 55 | 0.130 |
Why?
|
| Communication | 1 | 2019 | 457 | 0.130 |
Why?
|
| Isotretinoin | 1 | 2014 | 23 | 0.120 |
Why?
|
| Prognosis | 2 | 2020 | 3773 | 0.120 |
Why?
|
| Phytohemagglutinins | 1 | 2014 | 22 | 0.120 |
Why?
|
| Cysteine | 1 | 2015 | 136 | 0.120 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2017 | 345 | 0.120 |
Why?
|
| Adenosine Triphosphatases | 1 | 2015 | 154 | 0.120 |
Why?
|
| Health Services Accessibility | 1 | 2018 | 424 | 0.120 |
Why?
|
| Cells, Cultured | 3 | 2015 | 2880 | 0.120 |
Why?
|
| Smad7 Protein | 1 | 2014 | 7 | 0.120 |
Why?
|
| 25-Hydroxyvitamin D3 1-alpha-Hydroxylase | 1 | 2014 | 10 | 0.120 |
Why?
|
| Cell Communication | 1 | 2015 | 199 | 0.120 |
Why?
|
| Cohort Studies | 3 | 2017 | 2863 | 0.120 |
Why?
|
| CD3 Complex | 1 | 2014 | 134 | 0.120 |
Why?
|
| Interleukin-1beta | 1 | 2014 | 82 | 0.120 |
Why?
|
| Organ Specificity | 1 | 2015 | 272 | 0.120 |
Why?
|
| CD28 Antigens | 1 | 2014 | 90 | 0.120 |
Why?
|
| Dermatologic Agents | 1 | 2014 | 73 | 0.110 |
Why?
|
| Electron Transport | 1 | 2013 | 74 | 0.110 |
Why?
|
| Drug Resistance | 1 | 2014 | 232 | 0.110 |
Why?
|
| Cell Line | 1 | 2018 | 2495 | 0.110 |
Why?
|
| Societies, Medical | 1 | 2017 | 570 | 0.110 |
Why?
|
| Stress, Physiological | 1 | 2015 | 229 | 0.110 |
Why?
|
| Kidney Diseases | 1 | 1996 | 319 | 0.110 |
Why?
|
| Nuclear Proteins | 2 | 2015 | 726 | 0.110 |
Why?
|
| Interleukin-6 | 1 | 2014 | 261 | 0.110 |
Why?
|
| Drug Synergism | 1 | 2013 | 306 | 0.110 |
Why?
|
| Biomedical Research | 1 | 2017 | 398 | 0.110 |
Why?
|
| Patient Satisfaction | 1 | 2016 | 461 | 0.110 |
Why?
|
| Pathology, Clinical | 2 | 2024 | 34 | 0.110 |
Why?
|
| Lipopolysaccharides | 1 | 2014 | 293 | 0.110 |
Why?
|
| Urban Population | 1 | 2014 | 224 | 0.110 |
Why?
|
| Linkage Disequilibrium | 1 | 2014 | 477 | 0.100 |
Why?
|
| Sex Distribution | 2 | 2017 | 171 | 0.100 |
Why?
|
| Calcium | 1 | 2016 | 1172 | 0.100 |
Why?
|
| Genes, myc | 1 | 2012 | 39 | 0.100 |
Why?
|
| Spain | 1 | 2011 | 32 | 0.100 |
Why?
|
| Odds Ratio | 2 | 2011 | 684 | 0.100 |
Why?
|
| North Carolina | 1 | 2011 | 50 | 0.100 |
Why?
|
| Dexamethasone | 1 | 2013 | 344 | 0.100 |
Why?
|
| Academic Medical Centers | 1 | 2014 | 385 | 0.100 |
Why?
|
| Carrier Proteins | 1 | 2015 | 681 | 0.100 |
Why?
|
| Animals | 7 | 2022 | 27324 | 0.100 |
Why?
|
| Gene Expression Profiling | 1 | 2017 | 1429 | 0.090 |
Why?
|
| Gene Regulatory Networks | 1 | 2013 | 308 | 0.090 |
Why?
|
| Kidney | 1 | 1996 | 1145 | 0.090 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2011 | 159 | 0.090 |
Why?
|
| Introns | 1 | 2011 | 299 | 0.090 |
Why?
|
| Tretinoin | 1 | 2011 | 128 | 0.090 |
Why?
|
| Confidence Intervals | 1 | 2010 | 225 | 0.090 |
Why?
|
| Adjuvants, Immunologic | 1 | 2011 | 168 | 0.090 |
Why?
|
| Cardiovascular Diseases | 1 | 2016 | 705 | 0.090 |
Why?
|
| Europe | 1 | 2010 | 321 | 0.090 |
Why?
|
| Obesity | 1 | 2016 | 966 | 0.090 |
Why?
|
| Signal Transduction | 3 | 2015 | 3374 | 0.080 |
Why?
|
| Carcinoma | 1 | 2012 | 443 | 0.080 |
Why?
|
| RNA, Messenger | 1 | 2014 | 2011 | 0.080 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2007 | 80 | 0.070 |
Why?
|
| Child | 5 | 2018 | 7149 | 0.070 |
Why?
|
| Fatal Outcome | 1 | 2007 | 299 | 0.070 |
Why?
|
| Hepatitis B, Chronic | 1 | 2006 | 32 | 0.070 |
Why?
|
| Leukemia, Myeloid | 1 | 2007 | 249 | 0.070 |
Why?
|
| Survival Rate | 1 | 2010 | 1889 | 0.070 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2020 | 1265 | 0.060 |
Why?
|
| Acute Disease | 1 | 2007 | 841 | 0.060 |
Why?
|
| Family Health | 1 | 2006 | 162 | 0.060 |
Why?
|
| Down-Regulation | 2 | 2020 | 519 | 0.060 |
Why?
|
| Reproducibility of Results | 2 | 2024 | 2752 | 0.060 |
Why?
|
| Penetrance | 1 | 2024 | 45 | 0.060 |
Why?
|
| Loss of Function Mutation | 1 | 2024 | 46 | 0.060 |
Why?
|
| Medical History Taking | 1 | 2024 | 81 | 0.060 |
Why?
|
| Intestinal Neoplasms | 1 | 2024 | 64 | 0.060 |
Why?
|
| HEK293 Cells | 2 | 2019 | 638 | 0.060 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2018 | 665 | 0.050 |
Why?
|
| Antiviral Agents | 1 | 2006 | 475 | 0.050 |
Why?
|
| Pore Forming Cytotoxic Proteins | 1 | 2022 | 54 | 0.050 |
Why?
|
| Americas | 1 | 2022 | 19 | 0.050 |
Why?
|
| Cathartics | 1 | 2022 | 27 | 0.050 |
Why?
|
| Immune Tolerance | 2 | 2017 | 338 | 0.050 |
Why?
|
| Drug Discovery | 1 | 2022 | 107 | 0.050 |
Why?
|
| Pancreas | 1 | 2023 | 244 | 0.050 |
Why?
|
| Esophageal Neoplasms | 1 | 2024 | 332 | 0.050 |
Why?
|
| Administration, Oral | 2 | 2014 | 682 | 0.050 |
Why?
|
| Karyopherins | 1 | 2020 | 15 | 0.050 |
Why?
|
| Morphogenesis | 1 | 2022 | 206 | 0.050 |
Why?
|
| Mice, Transgenic | 2 | 2017 | 1574 | 0.050 |
Why?
|
| Quality Indicators, Health Care | 1 | 2021 | 146 | 0.040 |
Why?
|
| Quality Assurance, Health Care | 1 | 2021 | 225 | 0.040 |
Why?
|
| Cell Survival | 1 | 2022 | 982 | 0.040 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2020 | 111 | 0.040 |
Why?
|
| Butyrophilins | 1 | 2019 | 22 | 0.040 |
Why?
|
| Intraepithelial Lymphocytes | 1 | 2019 | 16 | 0.040 |
Why?
|
| GATA6 Transcription Factor | 1 | 2018 | 13 | 0.040 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2022 | 481 | 0.040 |
Why?
|
| SOX9 Transcription Factor | 1 | 2018 | 26 | 0.040 |
Why?
|
| Follow-Up Studies | 2 | 2016 | 3657 | 0.040 |
Why?
|
| Mixed Function Oxygenases | 1 | 2018 | 69 | 0.040 |
Why?
|
| Placebo Effect | 1 | 2018 | 30 | 0.040 |
Why?
|
| Bacteriological Techniques | 1 | 2018 | 39 | 0.040 |
Why?
|
| Wnt Signaling Pathway | 1 | 2018 | 97 | 0.040 |
Why?
|
| Quality Improvement | 1 | 2022 | 447 | 0.040 |
Why?
|
| DNA Copy Number Variations | 1 | 2018 | 177 | 0.040 |
Why?
|
| Non-Randomized Controlled Trials as Topic | 1 | 2017 | 6 | 0.040 |
Why?
|
| Reoviridae | 1 | 2017 | 6 | 0.040 |
Why?
|
| Interferon Regulatory Factor-1 | 1 | 2017 | 19 | 0.040 |
Why?
|
| Receptor, Interferon alpha-beta | 1 | 2017 | 20 | 0.040 |
Why?
|
| Mice, Inbred C57BL | 2 | 2017 | 3211 | 0.040 |
Why?
|
| Rectum | 1 | 2018 | 148 | 0.040 |
Why?
|
| Tertiary Care Centers | 1 | 2017 | 106 | 0.040 |
Why?
|
| Observational Studies as Topic | 1 | 2017 | 49 | 0.040 |
Why?
|
| Health Services Needs and Demand | 1 | 2017 | 103 | 0.030 |
Why?
|
| Genetic Engineering | 1 | 2017 | 115 | 0.030 |
Why?
|
| Child, Preschool | 2 | 2011 | 3717 | 0.030 |
Why?
|
| Pedigree | 1 | 2018 | 969 | 0.030 |
Why?
|
| Postoperative Care | 1 | 2017 | 229 | 0.030 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2019 | 394 | 0.030 |
Why?
|
| Mastectomy | 1 | 2018 | 245 | 0.030 |
Why?
|
| Colectomy | 1 | 2017 | 172 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2017 | 308 | 0.030 |
Why?
|
| Needs Assessment | 1 | 2017 | 157 | 0.030 |
Why?
|
| Hematuria | 1 | 1996 | 50 | 0.030 |
Why?
|
| Nutrition Surveys | 1 | 2016 | 109 | 0.030 |
Why?
|
| Receptors, Leukotriene | 1 | 2015 | 10 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 1 | 2019 | 866 | 0.030 |
Why?
|
| Arachidonate 5-Lipoxygenase | 1 | 2015 | 22 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 1 | 2018 | 921 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2019 | 948 | 0.030 |
Why?
|
| HSP27 Heat-Shock Proteins | 1 | 2015 | 33 | 0.030 |
Why?
|
| Consensus | 1 | 2017 | 356 | 0.030 |
Why?
|
| Transglutaminases | 1 | 2015 | 40 | 0.030 |
Why?
|
| Autophagy-Related Proteins | 1 | 2015 | 21 | 0.030 |
Why?
|
| Italy | 1 | 2015 | 107 | 0.030 |
Why?
|
| Sweden | 1 | 2014 | 40 | 0.030 |
Why?
|
| GTP-Binding Proteins | 1 | 2015 | 145 | 0.030 |
Why?
|
| Molecular Chaperones | 1 | 2015 | 122 | 0.030 |
Why?
|
| HSP70 Heat-Shock Proteins | 1 | 2015 | 115 | 0.030 |
Why?
|
| Cholestanetriol 26-Monooxygenase | 1 | 2014 | 7 | 0.030 |
Why?
|
| Cytochrome P450 Family 2 | 1 | 2014 | 4 | 0.030 |
Why?
|
| Heat-Shock Proteins | 1 | 2015 | 183 | 0.030 |
Why?
|
| Age Distribution | 1 | 2014 | 200 | 0.030 |
Why?
|
| Autoantibodies | 1 | 2015 | 268 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2018 | 1715 | 0.030 |
Why?
|
| Intestines | 1 | 2017 | 416 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2018 | 1796 | 0.030 |
Why?
|
| ras Proteins | 1 | 2014 | 130 | 0.030 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2014 | 146 | 0.030 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2014 | 164 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2017 | 833 | 0.030 |
Why?
|
| Risk | 1 | 2014 | 657 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2016 | 771 | 0.030 |
Why?
|
| Anti-Bacterial Agents | 1 | 2018 | 786 | 0.030 |
Why?
|
| DNA Glycosylases | 1 | 2012 | 25 | 0.030 |
Why?
|
| Blood Pressure | 1 | 2016 | 899 | 0.030 |
Why?
|
| Smoking | 1 | 2016 | 620 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2024 | 3443 | 0.020 |
Why?
|
| Dextran Sulfate | 1 | 2011 | 68 | 0.020 |
Why?
|
| G1 Phase | 1 | 2011 | 65 | 0.020 |
Why?
|
| Receptors, Interleukin-12 | 1 | 2011 | 9 | 0.020 |
Why?
|
| Azoxymethane | 1 | 2011 | 84 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2015 | 1533 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase 8 | 1 | 2011 | 23 | 0.020 |
Why?
|
| HCT116 Cells | 1 | 2011 | 155 | 0.020 |
Why?
|
| Gliadin | 1 | 2011 | 17 | 0.020 |
Why?
|
| Logistic Models | 1 | 2014 | 1212 | 0.020 |
Why?
|
| Cetuximab | 1 | 2011 | 117 | 0.020 |
Why?
|
| Coculture Techniques | 1 | 2011 | 173 | 0.020 |
Why?
|
| Interleukin-23 | 1 | 2011 | 57 | 0.020 |
Why?
|
| HeLa Cells | 1 | 2012 | 511 | 0.020 |
Why?
|
| Hypertension | 1 | 2016 | 741 | 0.020 |
Why?
|
| Interleukin-12 | 1 | 2011 | 109 | 0.020 |
Why?
|
| Seasons | 1 | 2011 | 237 | 0.020 |
Why?
|
| Registries | 1 | 2014 | 778 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 1 | 2012 | 1057 | 0.020 |
Why?
|
| Transfection | 1 | 2012 | 911 | 0.020 |
Why?
|
| Forkhead Transcription Factors | 1 | 2011 | 171 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2017 | 2362 | 0.020 |
Why?
|
| Neoplasms, Experimental | 1 | 2011 | 269 | 0.020 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2012 | 280 | 0.020 |
Why?
|
| Infant | 1 | 1996 | 3147 | 0.020 |
Why?
|
| Diabetes Mellitus | 1 | 2016 | 738 | 0.020 |
Why?
|
| Kidney Transplantation | 1 | 1996 | 849 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2015 | 2553 | 0.020 |
Why?
|
| ROC Curve | 1 | 2011 | 781 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2011 | 1130 | 0.020 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2011 | 306 | 0.020 |
Why?
|
| Research Design | 1 | 2011 | 597 | 0.020 |
Why?
|
| Surgical Equipment | 1 | 1967 | 4 | 0.020 |
Why?
|
| Dendritic Cells | 1 | 2011 | 442 | 0.020 |
Why?
|
| Peritoneal Dialysis | 1 | 1967 | 31 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2011 | 2014 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2011 | 967 | 0.020 |
Why?
|
| Antibodies, Monoclonal | 1 | 2011 | 1401 | 0.020 |
Why?
|
| Rats | 1 | 2011 | 4041 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2006 | 1149 | 0.010 |
Why?
|
| Fluorocarbon Polymers | 1 | 1967 | 3 | 0.000 |
Why?
|
| Catheterization | 1 | 1967 | 237 | 0.000 |
Why?
|